Viatris
Viatris Inc., a global healthcare company formed through the merger of Mylan and Upjohn, is headquartered in the United States. Established in 2020, Viatris operates in over 165 countries, focusing on the pharmaceutical industry with a commitment to providing access to high-quality medicines. The company’s core business areas include generic and specialty pharmaceuticals, biosimilars, and over-the-counter products. Viatris is renowned for its extensive portfolio, which features a diverse range of medications that address various health conditions, including chronic diseases and infectious diseases. Its unique approach combines a broad product offering with a strong emphasis on patient access and affordability. With a significant market presence, Viatris has achieved notable milestones, including the successful integration of its legacy companies and a commitment to sustainable healthcare solutions.
DitchCarbon Score
How does Viatris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viatris's score of 41 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Viatris's reported carbon emissions
In 2024, Viatris reported total carbon emissions of approximately 355,000,000 kg CO2e, with Scope 1 emissions accounting for about 95,000,000 kg CO2e. In the previous year, 2023, the company disclosed Scope 1 emissions of 0 kg CO2e in Great Britain, while Scope 2 emissions were approximately 295,000 kg CO2e, and Scope 3 emissions reached about 4,105,000 kg CO2e globally. Viatris has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030 from a 2020 baseline. Additionally, the company targets a 25% reduction in absolute Scope 3 emissions, which encompass purchased goods and services, capital goods, and upstream transportation and distribution, within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support global efforts to limit warming to 1.5°C. The company has also committed to reducing its Scope 1 emissions by 30% from a 2015 baseline by 2030, demonstrating a proactive approach to addressing its carbon footprint. Viatris's climate strategy reflects a commitment to sustainability and responsible environmental stewardship within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 299,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 354,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - |
| Scope 3 | 653,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Viatris is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
